Rights and permissions
About this article
Cite this article
Budesonide recommended as first-line therapy for mild to moderate Crohn's disease. Pharmacoecon. Outcomes News 505, 2 (2006). https://doi.org/10.2165/00151234-200605050-00004
Published:
Issue Date:
DOI: https://doi.org/10.2165/00151234-200605050-00004